Pharma Launch Leadership & Communication Practices to Manage Hostile Stakeholders

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Leadership and Communication Best Practices”

STUDY OVERVIEW

Pharma launch leaders often walk a tight rope when launching a novel breakthrough medicine. While they need to perfectly time the various launch activities to reach the drug’s full market potential, they cannot afford to ignore the likelihood of hostile responses from key stakeholder groups in case of an associated stigma or controversy around the condition or product.

Forward-looking pharma companies are not only developing fast response and early warning systems but are also establishing leadership involvement and communication guidelines to tactfully engage key stakeholder groups that may be hostile.

Best Practices, LLC engaged senior launch leadership from pharma companies and conducted extensive secondary research to identify effective strategies for managing hostile stakeholders during the launch of a breakthrough new medicine.

This study probes key aspects including: leadership involvement to ensure transparency and signal value accorded to the stakeholder; enabling rapid response to hostile issues; and communication practices that help prevent issues and soften hostile reaction.

KEY TOPICS

Leadership Best Practices
Developing Fast Response and Early Warning Systems
Communication Practices that Help Prevent Issues and Soften Hostile Voices

SAMPLE KEY FINDINGS

Fast-Response Structures: Pre-set roles, responsibilities, hierarchy, assignments, and procedures enable rapid response to hostile actions or issues.

Signal Respect: Senior leadership involvement signals the value you accord to the advocacy partner – even when they are opposed to your product.

METHODOLOGY

Best Practices, LLC engaged front-line executives at 11 companies across 9 therapeutic areas to conduct this analysis on hostile stakeholder management. Extensive secondary research was also conducted to identify industry best practices.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care

Companies Profiled:
Bayer; Boehringer Ingelheim; Eli Lilly and Company; Gilead Sciences; GlaxoSmithKline ; Johnson & Johnson; Merck; Pfizer; Roche; Sprout Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Leadership and Communication Best Practices

ID: 5700

Features:

Pages/Slides: 35

Published: 2021

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E09FD021487E4A040025876C00487EBD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-managing-hostile-stakeholders-during-launch-breakthrough-new-medicine-leadership-communication-best-practices?opendocument
18
19opendocument
2044.201.97.138
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB